B+
Bull case
25%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2025-10-26 · RankAlpha Sentiment AI
DYN
Dyne TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
50%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2025-10-26 · RankAlpha Sentiment AI
B-
Bear case
25%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2025-10-26 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2025-10-26
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Market sentiment is mixed: investors await clinical readouts and are sensitive to dilution risks, producing choppy trading and occasional optimism around partnership rumors [#Company-PR, #Market-News]. Short-term tone leans cautious due to funding needs, while long-term sentiment depends on pivotal data outcomes [#SEC-10Q].
RankAlpha Sentiment AI - 2025-10-26
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-eventPivotal or registrational trial readouts for DMD/other programsHigh impact
Upcoming clinical readouts or data updates from lead Duchenne muscular dystrophy (DMD) programs could re-rate the stock if results show clear efficacy/safety improvements vs. SOC [#PR-Company, #10-K-2024].
-catalystFunding / dilution eventsHigh impact
Equity raises or convertible financings to fund trials can dilute shareholders and pressure the share price; monitor SEC filings for shelf takedowns [#SEC-10QpFiling].
2026-03-31catalystNear-term data from early-stage SRP- or AAV-derived programsHigh impact
Early-stage biomarker or safety updates from preclinical/Phase 1 studies (e.g., target engagement, tolerability) may cause short-term volatility [#PR-Company, #SEC-8K].
Recommendation
N/A
No formal recommendation provided.
As of 2025-10-26 • Updated nightlySource: Internal modelMethodology